RNS

Released : October 16, 2017 07:00   RNS Number : 6267T MaxCyte, Inc. 16 October 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Declaration of Audit Remuneration   Maryland, USA - 16 October 2017:   MaxCyte (LSE: MXCT, MXCR), in order to assist investors in considering the resolutions
Oct 16, 2017
Released : October 05, 2017 18:32   RNS Number : 8773S MaxCyte, Inc. 05 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Oct 05, 2017
Released : October 05, 2017 18:31   RNS Number : 8770S MaxCyte, Inc. 05 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Oct 05, 2017
Released : September 28, 2017 17:15   RNS Number : 1589S MaxCyte, Inc. 28 September 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Notification of Annual General Meeting   Maryland, USA - 28 September 2017:   MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration
Sep 28, 2017
Released : September 19, 2017 07:00   RNS Number : 0903R MaxCyte, Inc. 19 September 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Results for the Six Months ended 30 June 2017   Maryland, USA - 19 September 2017 - MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the
Sep 19, 2017
Released : August 25, 2017 07:00   RNS Number : 9391O MaxCyte, Inc. 25 August 2017       MaxCyte, Inc. ("MaxCyte" or the "Company")   Notice of Half Year Results   Maryland, USA - 25 August 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
Aug 25, 2017
Released : July 20, 2017 18:02   RNS Number : 6906L MaxCyte, Inc. 20 July 2017       MaxCyte, Inc. ("MaxCyte" or the "Company")   Grant of Options   Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery,
Jul 20, 2017
Released : July 12, 2017 07:00   RNS Number : 7813K MaxCyte, Inc. 12 July 2017       MaxCyte, Inc. ("MaxCyte" or the "Company")   Trading Update   Maryland, USA - 12 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development,
Jul 12, 2017
Released : June 06, 2017 07:00   RNS Number : 2054H MaxCyte, Inc. 06 June 2017           MaxCyte, Inc. ("MaxCyte" or the "Company")   Cooperative Research and Development Agreement   MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease
Jun 06, 2017
Released : May 31, 2017 16:30   RNS Number : 7231G MaxCyte, Inc. 31 May 2017         MaxCyte, Inc. ("MaxCyte" or the "Company")   Total Voting Rights   Maryland, USA -31 May 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 22,435 new shares of common stock of $0.01
May 31, 2017